TB-500 in Australia: a thymosin β-4 research guide

TB-500 in Australia. TB-500 is the research-peptide market name for thymosin β-4 (Tβ4) — a naturally-occurring 43-amino-acid, N-terminally acetylated peptide and the principal G-actin-sequestering peptide in mammalian cells. It is referenced across actin-dynamics, cell-migration and tissue-repair research literature. This guide is a research-reference summary for Australian researchers: what the compound is, where it sits in the literature, and how research-grade material is verified. It makes no medical, performance, or human-use claim.

What TB-500 actually is (and the “17-residue fragment” myth)

TB-500 is thymosin β-4 — a 43-residue peptide that binds and sequesters monomeric G-actin, making it a central regulator of actin dynamics in research models. A persistent piece of misinformation describes TB-500 as a short “17-amino-acid fragment” of the molecule. The name did historically refer to a short active fragment, but in the research-peptide market “TB-500” is used for the full-length thymosin β-4 peptide — the form referenced here and reflected in the certificate of analysis. When you evaluate a supplier, the certificate is the arbiter: a real Tβ4 COA reports the full-length peptide, not a truncated fragment.

Actin dynamics and tissue-repair research

The molecular identity of thymosin β-4 as the actin-sequestering peptide was established by Safer and colleagues (Journal of Biological Chemistry, 1991), who showed Tβ4 and the actin-sequestering peptide “Fx” are indistinguishable. Sanders and colleagues (Proceedings of the National Academy of Sciences, 1992) then demonstrated that it regulates actin-polymerisation dynamics inside living cells. The broader actin-binding biochemistry and its downstream tissue-repair, cell-migration and angiogenesis research are surveyed in the review by Goldstein and colleagues (Expert Opinion on Biological Therapy, 2012). Across this literature TB-500 is used as an in-vitro research tool for probing actin dynamics — not as a treatment.

The BPC-157 pairing

TB-500 is most frequently referenced alongside BPC-157 in the canonical “soft-tissue” research pair. The two act on distinct pathways — actin dynamics versus growth-factor / nitric-oxide signalling — that converge on the tissue-repair research model, which is why researchers cite them together and why the two are co-lyophilised in the BPC-157 + TB-500 research blend (the “Wolverine” pairing) as a methodological convenience. For the growth-hormone-secretagogue side of recovery research, see the CJC-1295 GHRH research guide.

Identity, purity and the COA moat

In research peptides, the compound is only as useful as its verified identity and purity. Every batch of TB-500 supplied by Elite AU Peptides is independently HPLC-tested by Janoshik before it is listed. The measured purity is published on the TB-500 product page and in the lab-reports library — a real batch number, the measured percentage rather than a marketing figure, and a report you can verify independently at janoshik.com. TB-500 is stocked in 5mg and 10mg lyophilised vials; nothing is listed without a certificate on file.

Reconstitution and handling for research use

TB-500 ships as a lyophilised (freeze-dried) powder. For laboratory handling it is reconstituted with bacteriostatic water — for example, a 5mg vial in 2mL yields a 2.5mg/mL working stock, and a 10mg vial in 5mL yields 2mg/mL. Store the lyophilised powder at −20°C; once reconstituted, refrigerate at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Keep vials in their tamper-evident packaging until use and record batch numbers in your protocol notes.

Compliance and research-use framing

TB-500 is not TGA-approved and is not a therapeutic good. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption. We make no medical, performance, or human-use claim about this compound; the material above is a research-reference summary of the published thymosin β-4 literature, not guidance for any use. Researchers should consult primary peer-reviewed sources for actin-binding data, assay conditions, and protocol-specific reference values, and are responsible for the regulatory and institutional requirements that apply to their work.